Table 2. MSC products that have received regulatory approval.
| Name | MSC type | Indication | Country of approval (year) | Company |
| Alofisel | Human AT-MSC | Complex perianal fistulas in CD | Europe (2018) | TiGenix NV/Takeda |
| Prochymal (remestemcel-L) |
Human BM-MSC | GvHD | Canada (2012) New Zealand (2012) |
Osiris Therapeutics Inc./ Mesoblast Ltd. |
| Temcell HS Inj | Human BM-MSC | GvHD | Japan (2015) | JCR Pharmaceuticals |
| Queencell | Human AT-MSC | Subcutaneous tissue defects | South Korea (2010) | Anterogen Co. Ltd. |
| Cupistem | Human AT-MSC | Crohn’s fistula | South Korea (2012) | Anterogen Co. Ltd |
| Neuronata-R | Human BM-MSC | Amytrophic lateral sclerosis | South Korea (2014) | Corestem Inc. |
| Cartistem | Human UC-MSC | Knee articular cartilage defects | South Korea (2012) | Medipost Co. Ltd. |
| Stemirac | Human BM-MSC | Spinal cord injury | Japan (2018) | Nipro Corp. |
| Stempeucel | Human BM-MSC | Critical limb ischemia | India (2016) | Stempeutics Research PVT |
| Cellgram-AMI | Human BM-MSC | Acute MI | South Korea (2011) | Pharmicell Co. Ltd. |